00:31:48 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-08-29 Kvartalsrapport 2024-Q2
2024-05-15 Årsstämma 2024
2024-04-25 Bokslutskommuniké 2023
2023-10-11 Extra Bolagsstämma 2023
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-30 Ordinarie utdelning BRAINP 0.00 DKK
2023-05-26 Årsstämma 2023
2023-04-28 Bokslutskommuniké 2022
2022-09-29 Kvartalsrapport 2022-Q2
2022-09-02 Extra Bolagsstämma 2022
2022-05-19 Ordinarie utdelning BRAINP 0.00 DKK
2022-05-18 Årsstämma 2022
2022-04-29 Bokslutskommuniké 2021


ListaFirst North Denmark
IndustriVård & Omsorg
Brain+ är verksamma inom läkemedelsbranschen. Bolaget är specialiserade inom forskning och utveckling för behandling av demens och alzheimers. Produktportföljen inkluderar exempelvis kognitiv stimuleringsterapi. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs med störst närvaro inom Europa.
2023-10-16 13:37:22
  • At the 33[rd] Alzheimer's Europe conference, Brain+ shares insight and initial data from its recent work to validate tailored content for its CST-Therapist Companion v 2.0 product aimed to reduce variability in CST outcomes
  • At the annual meeting in INTERDEM, the most important pan-European network of researchers and clinicians disseminating psychosocial interventions in dementia, Brain+ presented its distinctive approach to digital delivery of CST
  • Brain+ is gaining recognition among patient groups, clinicians and researches as a key opinion leader on digitally delivered psychosocial, non-pharmaceutical interventions for the treatment of dementia

Copenhagen, Denmark, 16 October, 2023 - Brain+ A/S (Nasdaq First North: BRAINP)

Brain+ is solidifying its position as a key opinion leader in psychosocial, non-pharmacological therapeutic interventions for dementia, and the company has presented its distinctive approach to digital delivery of Cognitive Stimulation Therapy (CST) at two dementia conferences in October.

At the 33rd Alzheimer's Europe conference, held on 16-18 October 2023 in Helsinki, Finland, Brain+ will present a poster titled "Using Digital Technology to Standardise and Customise Cognitive Stimulation Therapy". The Poster shares insight into the methodologies and early data behind the development and validation of content for the company's first product for digital delivery of CST, CST-Therapist Companion. CST-Therapist Companion provides CST activities tailored to different cognitive severities and has potential to support large-scale implementation of CST and reduce variability in outcomes. Alzheimer's Europe is a longtime collaborator of Brain+, having participated in several of the company's innovation projects for the development of digital dementia technologies and products.

At the annual INTERDEM business meeting, held on 15-16 October 2023 in connection with the Alzheimer's Europe conference, Brain+ showcased its digital CST product offerings to international clinical experts on dementia, including leading CST experts.  INTERDEM is a pan-European network of researchers collaborating in the research and dissemination of early, timely and high-quality psychosocial INTERvention in DEMentia; thus enhancing best practice therapeutic initiatives in clinical practice and improving quality of life of people with dementia and their caregivers. Notably, Brain+ has a unique standing as the sole company represented within the INTERDEM network.

Participation at key opinion leadership meetings in dementia is pivotal for Brain+, Participation at leading dementia conferences is of core value to Brain+, serving a dual purpose: Firstly, it ensures that the company's employees stay at the forefront of the most recent findings and knowledge on dementia pathology and therapy, providing insight to feed into the development of cutting-edge therapeutic solutions, asserting also in-house the company's leadership in the field. Secondly, it supports the establishment of in-house clinicians as recognized experts and facilitates engaging international connections to build trust with clinicians, academics, and advocacy groups, a crucial factor for the integration of Brain+ products into health systems. On top of strong clinical and health economic evidence and real-life experience and reference, network and trust are crucial factors to facilitate the adoption of Brain+ offered products into clinical dementia practice and care.

Last day of TO2 warrant exercise - Pre-commitments received for almost 50%

Today, Monday 16 October 2023 is the last day for holders of Brain+ TO2 warrants to exercise their warrants and subscribe for new shares in the company at the price of DKK 0.20.

On Thursday, 12 October 2023, Brain+ announced commitments from the company's largest shareholders reaching almost 50% of the total outstanding, including commitments from members of its board and management to both exercise all their warrants and act as guarantors for at total amount of DKK 0.4 million.   

Contact Information

CEO and Co-founder: Kim Baden-Kristensen, + 45 31393317 (SMS), kim@brain-plus.com

Mission:  Bringing effective digitally-delivered dementia therapies to those in need, serving a million people with dementia, care-givers and clinicians by 2030.